Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
(NASDAQ:EVAR)
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced that trading of Lombard Medical, Inc. (Nasdaq:EVAR), the specialist medical device company focused on endovascular aortic repair of abdominal aortic aneurysms, commenced on The NASDAQ Stock Market on April 25, 2014.
Lombard Medical’s lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced abdominal aortic aneurysm (AAA) disease. Aorfix is the only stent graft approved by the U.S. Food and Drug Administration for AAA neck angulations of up to 90 degrees and is currently being commercialized worldwide.
“NASDAQ congratulates Lombard Medical on its successful initial public offering, and we look forward to celebrating more milestones with them in the years to come,” said Adam Kostyál, Senior Vice President, Corporate Client Group, NASDAQ OMX.
By listing with NASDAQ, Lombard Medical Technologies joins some of the world’s largest and most revolutionary healthcare companies. NASDAQ has been the exchange of choice to over 97 percent of healthcare companies that have listed on the U.S. markets year-to-date in 2014.
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets.
As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients.
